Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumorsMatteo Simonelli, Armando Santoro, Paolo Andrea Zucali et al.|European Journal of Cancer|2012Cited by 13
NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapiesElena Ardini, Marina Ciomei, Nilla Avanzi et al.|European Journal of Cancer|2016Cited by 1